August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
IASLC Highlights FDA Approval of VENTANA MET (SP44) RxDx Assay for NSCLC
Jun 29, 2025, 13:27

IASLC Highlights FDA Approval of VENTANA MET (SP44) RxDx Assay for NSCLC

International Association for the Study of Lung Cancer shared a post on LinkedIn:

“VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC.

Read more in ILCN.”

Read OncoDaily’s Special Article on NSCLC․

NSCLC Lung cancer